Serum Level of Growth-Associated Protein 43 Is Associated with First-Episode Schizophrenia Patients without Antipsychotic Drugs Treatment

Libin Xiao,1 Xiaowei Tang,2 Xiuxiu Hu,3 Xiaotang Feng,1 Ronglan Gong,1 Fujun Wang,1 and Xiangrong Zhang4

1Department of Psychiatry, Nanjing Qinglongshan Mental Hospital, Nanjing 211123, Jiangsu, China
2Affiliated WuTuiShan Hospital of Medical College of Yangzhou University, Yangzhou 225003, Jiangsu, China
3The Second People's Hospital of Jiangning District, Nanjing 211103, Jiangsu, China
4Department of Geriatric Psychiatry, Affiliated Brain Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu, China

Correspondence should be addressed to Xiangrong Zhang; drxrz@hotmail.com

Received 26 March 2022; Revised 23 April 2022; Accepted 26 April 2022; Published 16 May 2022

Nerve growth-associated protein 43 (GAP43) is closely related to nerve growth and development processes such as nerve development, axonal regeneration, and synaptic remodeling and is one of the important markers of neuronal damage. Therefore, in our study, enzyme-linked immunosorbent assay (ELISA) was used to analyze the serum level of GAP43 protein in schizophrenia patients (n = 188), healthy controls (n = 200), and bipolar disorder patients (n = 200). The positive and negative syndrome scale (PANSS) was used to evaluate the mental status of schizophrenia patients, and the Scale of Social Function in Psychosis Inpatients (SSPI) was used to evaluate the social function of schizophrenia patients. According to this study, we found the serum GAP43 level was significantly higher in schizophrenia patients than in bipolar disorder patients, while serum GAP43 levels in bipolar disorder patients were significantly higher than those in control group. When the cut-off value was set as 2.328 ng/mL, the area under the curve (AUC) of serum GAP43 was 0.7795 (95% CI: 0.7431–0.8158) for diagnosis of schizophrenia. The sensitivity and specificity were 92.02% and 65.25%, respectively. However, no correlation between serum GAP43 and the total scores of PANSS scale in schizophrenia patients as well as between serum GAP43 level and SSPI were observed. Therefore, we believe that GAP43 may be a potential diagnostic marker for schizophrenia.

1. Introduction

Schizophrenia is a serious mental illness caused by a combination of genetic and environmental factors [1, 2]. Schizophrenia usually presents severe psychotic symptoms and a wide range of cognitive functional deficits, such as learning, memory, executive function, and attention disorders [3, 4]. According to the theory of mental development, the core of various symptoms of schizophrenia is abnormal neuronal connectivity throughout the brain and defects in information processing between various neural microcircuits, that is, defects in synaptic plasticity [5]. Previous studies have found that the occurrence of schizophrenia is closely associated with factors related to nerve growth and development, such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), fibroblast growth factor (FGF2), and activity-dependent neuroprotective factor (ADNP) [6]. Our previous study suggested that serum BDNF may be an inappropriate biomarker for deficit schizophrenia (DS), but higher serum glial cell line-derived neurotrophic factor (GDNF) levels were associated with better cognitive performance in DS patients [7].

Growth-associated protein 43 (GAP43) is closely related to nerve growth and development processes such as nerve development, axonal regeneration, and synaptic remodeling...
in the body [8]. It shows high expression during neuronal development and synaptogenesis and continues to be expressed in the presynaptic terminal region and association cortex of the adult brain [9]. Nemes et al. [10] found that GAP43 baseline expression was increased in epileptic rats when compared with nonepileptic rats, suggesting that GAP43 can be used as a new target for the diagnosis, treatment, and prevention of epileptogenesis. Sandelius et al. [11] found that cerebrospinal fluid concentration of GAP43 presented a transient increase after ischemic stroke. Although it has been proven the association of GAP43 with a variety of neurogenic diseases, no relevant studies investigate the relationship between serum GAP43 and the development of first-episode schizophrenia, as well as its clinical symptoms. Although GAP43 is mainly expressed in the nervous system, studies have found that metabolites such as proteins in the brain of patients with schizophrenia enter the cerebrospinal fluid through the damaged blood-brain barrier, and its specific changes dynamically reflect the metabolic state of the brain and the stability of the internal environment [12, 13]. Therefore, in this study, we detect the GAP43 level in the serum of first-episode schizophrenic patients who did not receive antipsychotic drugs. Additionally, the difference of GAP43 expression among patients with schizophrenia and with bipolar disorder and healthy donors is analyzed to explore their correlation with clinical parameters and to study the diagnostic power of GAP43 for schizophrenia.

2. Methods

2.1. Subjects. Patients with schizophrenia who visited Affiliated WuTaiShan Hospital of Medical College of Yangzhou University from April 2017 to March 2018 were selected. Inclusion criteria: (1) patients met the diagnostic criteria of Schizophrenia, based on the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V); (2) newly diagnosed patients; (3) patients did not take antipsychotic drugs; (4) patients without a history of electroconvulsive therapy; (5) right-handed patients. Exclusion criteria: (1) individuals with central nervous system diseases or other major physical diseases, such as Alzheimer’s disease, Parkinson’s disease, uncontrolled hypertension, severe cardiovascular, cerebrovascular, pulmonary disease, and thyroid disease; (2) alcohol and drug dependence or abusers; (3) individuals with red, green, and blue color blindness or weak color or hearing impairment. A total of 200 patients were recruited in the control group.

Patients who visited the hospital during the same period and were diagnosed with bipolar disorder and were selected in the affective disorder group. Inclusion criteria: (1) patients diagnosed with bipolar disorder by DSM-V, and all patients were diagnosed according to the International Classification of Diseases-10 (ICD-10); (2) other criteria were the same as the study group. Exclusion criteria were the same as the study group. A total of 200 patients were included in the affective disorder group.

2.2. Study Methods

2.2.1. Data Collection. Baseline data such as gender and age at enrollment were collected for the subjects in the three groups. The average age of healthy controls was $(25.04 \pm 3.11)$ years, and 97 cases were male. The mean age of patients in the bipolar disorder group was $(24.73 \pm 3.18)$ years, and 96 cases were male. The mean age of the patients in the Schizophrenia group was $(24.94 \pm 3.14)$ years, and 90 cases were male. The Positive and Negative Symptom Scale (PANSS) was used to assess the mental status of patients in the study group (higher score means severer the psychiatric symptoms); the Scale of Social Function in Psychosis (SSPI) was used to assess the social function of patients in the study group (higher score means better the patient’s social functioning).

2.2.2. Sample Collection and Detection of the Serum Level of GAP43. A total of 3 mL of venous blood was collected in a clotting tube from the subjects in each group. The serum was separated by a fasting centrifugation at 3000 r/min for 15 min and then stored at $-80^\circ$C till use. Serum GAP43 was detected by enzyme-linked immunosorbent assay (ELISA) kit (Promega, USA). The experimental procedures were performed according to the instructions, which were briefly described as follows: samples, standards, and HRP-labeled detection antibody were added to the wells precoated with the GAP43 capture antibody, incubated at room temperature, and washed thoroughly. After color development with the substrate TMB, the absorbance (OD value) was measured with a microplate reader at a wavelength of 450 nm, and the concentration of each sample was calculated based on the obtained standard curve. These replicate each sample.

2.2.3. Statistical Analysis. Data collection was performed using Excel version 2019, and data analysis was conducted using SPSS (version 22.0; SPSS Inc., Chicago, IL,
USA) software and Graphpad prism (San Diego, CA, USA). Normally, continuous variables were expressed as mean ± standard deviation (mean ± SD), and the t-test was used for pairwise comparisons between independent samples; nonnormal continuous variables were expressed as median (P25, P75), and the Mann–Whitney U test was used for pairwise comparisons between independent samples. Categorical variable was expressed as n (%), and pairwise comparisons between independent samples were performed using the χ² test. The diagnostic efficacy of GAP43 for schizophrenia was evaluated using the area under the curve (AUC) of receiver operating characteristic (ROC) curve. Correlation analysis was performed using the Kendall correlation and Spearman correlation analysis. All assays were two-tailed. Differences were considered statistically significant when p < 0.05.

3. Results

3.1. Demographic Data. The demographic data of healthy controls, bipolar disorder, and schizophrenia patients are shown in Table 1. There are no statistically significant differences between healthy controls, bipolar disorder, and schizophrenia patients in age, gender, fasting state, and time of day (p > 0.05).

3.2. Comparison of Serum Level of GAP43 among Three Groups. The serum level of GAP43 in the healthy control, bipolar disorder, and schizophrenia patients are shown in Figure 1. According to the results of statistical analysis, the serum GAP43 level of bipolar disorder patients was significantly higher than that of the healthy control group (p = 0.008), and the serum GAP43 level of schizophrenia patients was significantly higher than that of bipolar disorder patients (p = 0.009).

3.3. Diagnostic Efficacy of Serum GAP43 in Schizophrenia. The ROC was used to analyze the diagnostic efficacy of serum GAP43 in schizophrenia, and the result is shown in Figure 2. The analysis result showed that the AUC was 0.7795 (95%CI: 0.7431–0.8158), the cut-off value was 2.328 ng/mL, the likelihood ratio value was 2.648, the sensitivity was 92.02%, and the specificity was 65.25%.

3.4. Correlation between Serum GAP43 Level and Mental Status in Schizophrenia Patients. Kendall correlation and spearman correlation analysis revealed that no correlations between the serum level of GAP43 and positive symptom score, negative symptom score, general mental status score, and PANSS total score in patients with schizophrenia (all p > 0.05, Table 2).

3.5. Correlation between the Serum GAP43 Level and Social Function in Schizophrenia Patients. Kendall correlation and spearman correlation analysis revealed neither correlations between serum GAP43 levels and SSPI total score nor various scores in schizophrenia patients (p > 0.05, Table 3).

4. Discussion

In this study, we investigated the differences in serum GAP43 level between schizophrenia patients, healthy controls, and bipolar disorder patients. The results showed that the serum GAP43 level was significantly higher in schizophrenia patients than other two groups. GAP43 plays an important role in long-term and short-term synaptic plasticities, such as neurotransmitter release, endocytosis and synaptic vesicle recycling, long-term potentiation, and spatial memory formation and learning. It has been shown that GAP43 expression is associated with schizophrenia in cadaveric brains [14]. In the adult brain, GAP43 remains enriched primarily in association cortices and in the hippocampus, and it is suggested GAP43 marks circuits involved in the acquisition, processing, and/or storage of new information [15]. A controlled study of 17 schizophrenia patients showed that the GAP43 level was increased in the hippocampus; this may be due to the development of re-active synapses caused by developmental disorders or injury, indicating an abnormal hippocampal function in schizophrenia patients [16]. A study using real-time quantitative PCR to measure activity-dependent gene levels in cerebellar cortical glutamatergic neurons showed that GAP43 mRNA levels were significantly increased in schizophrenia patients, proposing that glutamatergic neurons may be hyperactive in the cerebellar cortex of schizophrenia patients, resulting in short-term plasticity abnormalities [17]. Through the study of cadaveric brains, GAP43 expression was found to be associated with schizophrenia. Some researchers measured the expression level of GAP43 mRNA in the brain tissue of 37 schizophrenia patients and 37 control groups after death, and the results showed that the expression level of GAP43 mRNA in the dorsolateral prefrontal cortex of schizophrenia patients was reduced [18]. Another study showed that schizophrenia was associated with a disordered organization of synaptic connections in different cortical-related regions of the human brain, and the increased level of GAP43 was a manifestation of this dysfunctional organization [15]. However, studies on both the anterior cingulate cortex and medial temporal lobe did not find significant alterations in the expression of GAP43 [19, 20]. In this study, peripheral blood serum was collected from patients to measure GAP43 expression level, and the change degree of serum GAP43 expression level in schizophrenia patients was elucidated. Compared with the detection of protein or mRNA levels in tissues mentioned in the above reports, the serum sample detection is easy to obtain and can achieve rapid noninvasive detection. Importantly, the expression levels of GAP43 in the serum of schizophrenia patients and bipolar disorder are also significantly different, indicating that GAP43 has clinical application value as a diagnostic marker for schizophrenia.

The correlation study showed that there was no correlation between the content of GAP43 protein in the serum of patients with schizophrenia and the PANSS total score, nor
positive symptom score, nor negative symptom score, and nor general pathological symptom score, indicating that although the serum GAP43 protein was increased in schizophrenia patients at the onset, its increase degree was not correlated with the severity of positive symptoms, negative symptoms, and general pathological symptoms of schizophrenia. It is speculated that GAP43 may not be a responsible factor for psychotic symptoms in the acute phase of schizophrenia. Moreover, no correlation between the content of GAP43 protein in serum and the SSPI scores was observed, indicating that the content of GAP43 protein in serum of patients was not correlated with the severity of cognitive impairment such as patient abstract generalization, cognitive transfer, attention, working memory, information extraction, classification maintenance, classification conversion, stimulation recognition and processing, sensory input, and motor output.

Besides these, the study on the diagnostic efficacy of GAP43 for schizophrenia showed when the serum level of GAP43 $\geq 2.328$ ng/mL was considered as the abnormal value, the diagnostic sensitivity was 92.02%, and the
specificity was 65.25%. Due to high sensitivity but specificity, patients with schizophrenia can be effectively distinguished from nonschizophrenic donors by detecting the serum level of GAP43, but serum GAP43 was not a "mirror" for GAP43 in CNS. In recent years, extensive studies have been conducted on the expression levels of serum-related factors in schizophrenia. Li C et al. [21] found that ErbB4, BDNF, and TET1 were independent predictors of schizophrenia, and the combination has a high diagnostic accuracy for schizophrenia. He et al. [22] investigated the potential of serum miRNAs as diagnostic markers for schizophrenia, and the results showed that the combination of two miRNAs, miR-432-5p and miR-449a, could be potentially used as a biomarker for the diagnosis of schizophrenia. The findings may help psychiatrists to overcome the current dilemma facing the diagnosis of schizophrenia. Based on our and previous studies, we believe that GAP43, as an important nerve growth-associated factor, has the advantages of simplicity, convenience, and high diagnostic accuracy compared with the method of combined diagnosis of multiple proteins or combined diagnosis of multiple miRNAs.

This study also has some limitations. First, GAP43 was not correlated with the social function and mental status of patients with schizophrenia, indicating that GAP43 may not be correlated with the severity of schizophrenia, which limited the application of GAP43 in schizophrenia that can only be used as a disease diagnostic marker. Second, GAP43 has a certain diagnostic efficacy for schizophrenia, but we did not compare transversely with the diagnostic ability of other diagnostic markers. Third, whether the serum level of GAP43 is consistent with the level changes in brain tissue and cerebrospinal fluid needs to be elucidated by further studies.

In summary, GAP43 could be potentially used as a diagnostic marker in schizophrenia patients rather than a marker of disease severity. Since GAP43 has high sensitivity but poor specificity, it should be combined with other diagnostic methods when used in the diagnosis of schizophrenia to further improve specificity.

Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Ethical Approval
The Ethics Review Committee of Affiliated WuTaiShan Hospital of Medical College of Yangzhou University approved the study (no. 201602). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent
Informed written consent was obtained from all participants prior to the commencement of the study.

Conflicts of Interest
The authors declare that there are no conflicts of interest.

Authors’ Contributions
Xiangrong Zhang and Xiaowei Tang designed the study. Xiaowei Tang treated the patients. Libin Xiao and Xiaotang Feng performed the experiments. Libin Xiao and Xiuxiu Hu analyzed the data. Xiangrong Zhang, Xiaowei Tang, Libin Xiao, and Xiuxiu Hu discussed the organization of the manuscript. Libin Xiao wrote the manuscript. All authors critically reviewed the manuscript. Xiangrong Zhang, Xiaowei Tang, and Xiuxiu Hu edited the manuscript. Fujun Wang and Ronglan Gong supervised the work.

Acknowledgments
The authors would like to thank Dr. Yuanyuan Liu, Sheng Wu, and Siwen Yang from Nanjing Qinglongshan Mental Hospital, as well as Dr. Ju Gao from Affiliated Brain Hospital of Nanjing Medical University, for helping and supporting the study. This study was supported by the Major Chronic Disease Project of Key R&D Program of Ministry of Science and Technology (2018YFC1314300), General Project of National Natural Science Foundation of China (81971255), General Project of Social Development of Jiangsu Provincial Department of Science and Technology (BE2019610), Key Medical Talent Project of Jiangsu Province (ZDRCA2016075), and Nanjing Medical Science and Technology Development Fund Project (YK16290).

References
[1] X. L. Chao, S. Z. Jiang, J. W. Xiong et al., “The association between serum insulin-like growth factor 1 and cognitive impairments in patients with schizophrenia,” Psychiatry Research, vol. 285, p. 112731, 2020.
[2] P. H. Lysaker, M. L. Pattison, B. L. Leonhardt, and S. J. L. Phelps, “Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments,” World Psychiatry, vol. 17, no. 1, pp. 12–23, 2018.
[3] A. Tripathi, S. K. Kar, and R. Shukla, “Cognitive deficits in schizophrenia: understanding the biological correlates and remediation strategies,” Clinical Psychopharmacology and Neuroscience, vol. 16, no. 1, pp. 7–17, 2018.
[4] M. H. Xiu, D. M. Wang, X. D. Du et al., “Interaction of BDNF and cytokines in executive dysfunction in patients with chronic schizophrenia,” Psychoneuroendocrinology, vol. 108, pp. 110–117, 2019.
[5] G. Gilmour, S. Porcelli, V. Bertaina-Anglade et al., “Relating constructs of attention and working memory to social withdrawal in Alzheimer’s disease and schizophrenia: issues regarding paradigm selection,” Neuroscience & Biobehavioral Reviews, vol. 97, pp. 47–69, 2019.
[6] X.-S. Li, H.-T. Wu, Y. Yu et al., “Increased serum FGF2 levels in first-episode, drug-free patients with schizophrenia,” Neuroscience Letters, vol. 686, pp. 28–32, 2018.
[7] X. Tang, C. Zhou, J. Gao et al., “Serum BDNF and GDNF in Chinese male patients with deficit schizophrenia and their
relationships with neurocognitive dysfunction,” *BMC Psychiatry*, vol. 19, no. 1, p. 254, 2019.

[8] M. R. Holahan, "A shift from a pivotal to supporting role for the growth-associated protein (GAP-43) in the coordination of axonal structural and functional plasticity,” *Frontiers in Cellular Neuroscience*, vol. 11, p. 266, 2017.

[9] K.-A. Saal, D. Galter, S. Roebel, M. Bähr, and L. P. Tönges, "Altered expression of growth associated protein-43 and rho kinase in human patients with Parkinson’s disease,” *Brain Pathology*, vol. 27, no. 1, pp. 13–25, 2017.

[10] A. D. Nemes, K. Ayasoufi, Z. Ying, Q.-G. Zhou, H. Suh, and I. M. Najm, “Growth associated protein 43 (GAP-43) as a novel target for the diagnosis, treatment and prevention of epileptogenesis,” *Scientific Reports*, vol. 7, no. 1, p. 17702, 2017.

[11] Å. Sandelius, N. C. Cullen, Å. Källen et al., "Transient increase in CSF GAP-43 concentration after ischemic stroke,” *BMC Neurology*, vol. 18, no. 1, p. 202, 2018.

[12] N. Sinnax, M. Amatoury, V. Merheb, S. Ramanathan, R. C. Dale, and F. Brilot, "Autoantibodies in movement and psychiatric disorders: updated concepts in detection methods, pathogenicity, and CNS entry,” *Annals of the New York Academy of Sciences*, vol. 1351, no. 1, pp. 22–38, 2015.

[13] D. Janigro, D. M. Bailey, S. Lehmann et al., "Peripheral blood and salivary biomarkers of blood-brain barrier permeability and neuronal damage: clinical and applied concepts,” *Frontiers in Neurology*, vol. 11, p. 577312, 2021.

[14] S. J. Lee, K. R. Kim, S. Y. Lee, and S. K. An, "Impaired social and role function in ultra-high risk for psychosis and first-episode schizophrenia: its relations with negative symptoms,” *Psychiatry Investigation*, vol. 14, no. 5, pp. 539–545, 2017.

[15] N. I. Perrone-Bizzozero, A. C. Sower, E. D. Bird, L. I Benowitz, K. J. Ivins, and R. L. Neve, "Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia,” *Proceedings of the National Academy of Sciences*, vol. 93, no. 24, pp. 14182–14187, 1996.

[16] K. Blennow, N. Bogdanovic, C.-G. Gottfries, and P. Davidsson, "The growth-associated protein GAP-43 is increased in the hippocampus and in the gyrus cinguli in schizophrenia,” *Journal of Molecular Neuroscience*, vol. 13, no. 1-2, pp. 101–110, 1999.

[17] R. D. Paz, N. C. Andreasen, S. Z. Daoud et al., "Increased expression of activity-dependent genes in cerebellar glutamatergic neurons of patients with schizophrenia,” *American Journal of Psychiatry*, vol. 163, no. 10, pp. 1829–1831, 2006.

[18] S. J. Fung, S. Sivagnanasundaram, and C. S. Weickert, "Lack of change in markers of presynaptic terminal abundance alongside subtle reductions in markers of presynaptic terminal plasticity in prefrontal cortex of schizophrenia patients,” *Biological Psychiatry*, vol. 69, no. 1, pp. 71–79, 2011.

[19] S. L. Eastwood and P. J. Harrison, "Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP-43 and the complexins,” *Brain Research Bulletin*, vol. 55, no. 5, pp. 569–578, 2001.

[20] M. J. Webster, C. Shannon Weickert, M. M. Herman, T. M. Hyde, and J. E. Kleinman, "Synaptophysin and GAP-43 mRNA levels in the hippocampus of subjects with schizophrenia,” *Schizophrenia Research*, vol. 49, no. 1-2, pp. 89–98, 2001.

[21] C. Li, H. Tao, X. Yang et al., "Assessment of a combination of Serum Proteins as potential biomarkers to clinically predict Schizophrenia,” *International Journal of Medical Sciences*, vol. 15, no. 9, pp. 900–906, 2018.

[22] K. He, C. Guo, M. Guo, and S. Tong, "Identification of serum microRNAs as diagnostic biomarkers for schizophrenia,” *Hereditas*, vol. 156, no. 1, p. 23, 2019.